For the third quarter of FY26, Veerhealth Care Limited posted a standalone net profit of Rs 0.40 crore, marking a 474.18% year-on-year increase. Total income rose 73.13% to Rs 6.96 crore during the same period.
Earnings before interest, tax, depreciation and amortisation (EBITDA) stood at Rs 0.94 crore, up 181.44% from a year earlier. EBITDA margin improved to 13.36%, while net profit margin rose to 5.81%.
Veerhealth, which operates its Ayurveda-focused brand Ayuveer, manufactures ayurvedic medicines and oral care products using natural ingredients. The company said it expects a significant rise in exports to the United States following tariff reductions and improved regulatory access.
It has received clearance from the U.S. Food and Drug Administration (USFDA), enabling exports of over-the-counter (OTC) drug products to the US. The approval also opens doors to other international markets, positioning the firm among a limited number of small-cap Indian healthcare companies with a USFDA-approved manufacturing facility.
The company said it is also scaling up production under the medical device category in the US market, having completed the required formalities with the regulator. In addition, it has secured approval from the Food and Drug Authority in Gujarat to manufacture personal care products for a leading marketplace firm.
Veerhealth is expanding its digital footprint, with Ayuveer products now listed on Amazon, Flipkart and Myntra. It has also begun production at a new facility with in-house plastic moulding for packaging.
The company said it expects revenues of Rs 45–50 crore in FY27, with a longer-term target of reaching Rs 100 crore in revenue within 24 months, alongside a projected profit margin of 10%.
